TERT promoter mutation analysis for blood-based diagnosis and monitoring of gliomas.

CONCLUSIONS: Our results demonstrate the feasibility of detecting circulating cfDNA TERT promoter mutations in glioma patients with clinically relevant sensitivity and specificity. PMID: 33051308 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/33051308?dopt=Abstract

Source: Clinical Cancer Research - October 13, 2020 Category: Cancer & Oncology Authors: Muralidharan K, Yekula A, Small JL, Rosh ZS, Kang KM, Wang L, Lau S, Zheng H, Lee H, Bettegowda C, Chicoine MR, Kalkanis S, Shankar GM, Nahed BV, Curry WT, Jones PS, Cahill DP, Balaj L, Carter BS Tags: Clin Cancer Res Source Type: research